PURPOSE: Inconsistencies and omissions in drug-drug interaction (DDI) management guidelines may lead to harm and suboptimal therapy. The purpose of this study was to define a checklist for DDI management guidelines to help developers produce high-quality guidelines that will support healthcare providers in clinical practice. METHODS: We carried out a two-round Delphi process with an international panel of healthcare providers, most of whom are pharmacists involved in providing DDI information, in order to select those items that should be addressed in DDI management guidelines (including grading systems that could be used). RESULTS: Twenty-three panellists reached consensus on 19 items in two main domains. These were consolidated into a checklist of 15 elements for standardized reporting in management guidelines. For each element a description is provided to specify what information should be documented in that specific element. CONCLUSIONS: It was possible to reach a broad consensus on which relevant items should be included in a checklist for the development of DDI management guidelines.
PURPOSE: Inconsistencies and omissions in drug-drug interaction (DDI) management guidelines may lead to harm and suboptimal therapy. The purpose of this study was to define a checklist for DDI management guidelines to help developers produce high-quality guidelines that will support healthcare providers in clinical practice. METHODS: We carried out a two-round Delphi process with an international panel of healthcare providers, most of whom are pharmacists involved in providing DDI information, in order to select those items that should be addressed in DDI management guidelines (including grading systems that could be used). RESULTS: Twenty-three panellists reached consensus on 19 items in two main domains. These were consolidated into a checklist of 15 elements for standardized reporting in management guidelines. For each element a description is provided to specify what information should be documented in that specific element. CONCLUSIONS: It was possible to reach a broad consensus on which relevant items should be included in a checklist for the development of DDI management guidelines.
Authors: Ylva Böttiger; Kari Laine; Marine L Andersson; Tuomas Korhonen; Björn Molin; Marie-Louise Ovesjö; Tuire Tirkkonen; Anders Rane; Lars L Gustafsson; Birgit Eiermann Journal: Eur J Clin Pharmacol Date: 2009-02-11 Impact factor: 2.953
Authors: Gordon H Guyatt; Andrew D Oxman; Gunn E Vist; Regina Kunz; Yngve Falck-Ytter; Pablo Alonso-Coello; Holger J Schünemann Journal: BMJ Date: 2008-04-26
Authors: Daniel C Malone; Jacob Abarca; Philip D Hansten; Amy J Grizzle; Edward P Armstrong; Robin C Van Bergen; Babette S Duncan-Edgar; Steven L Solomon; Richard B Lipton Journal: J Am Pharm Assoc (2003) Date: 2004 Mar-Apr
Authors: Richard T Scheife; Lisa E Hines; Richard D Boyce; Sophie P Chung; Jeremiah D Momper; Christine D Sommer; Darrell R Abernethy; John R Horn; Stephen J Sklar; Samantha K Wong; Gretchen Jones; Mary L Brown; Amy J Grizzle; Susan Comes; Tricia Lee Wilkins; Clarissa Borst; Michael A Wittie; Daniel C Malone Journal: Drug Saf Date: 2015-02 Impact factor: 5.606
Authors: Hugh Tilson; Lisa E Hines; Gerald McEvoy; David M Weinstein; Philip D Hansten; Karl Matuszewski; Marianne le Comte; Stefanie Higby-Baker; Joseph T Hanlon; Lynn Pezzullo; Kathleen Vieson; Amy L Helwig; Shiew-Mei Huang; Anthony Perre; David W Bates; John Poikonen; Michael A Wittie; Amy J Grizzle; Mary Brown; Daniel C Malone Journal: Am J Health Syst Pharm Date: 2016-04-15 Impact factor: 2.637
Authors: Rianne A Weersink; Margriet Bouma; David M Burger; Joost P H Drenth; Nicole G M Hunfeld; Minke Kranenborg; Margje H Monster-Simons; Sandra A W van Putten; Herold J Metselaar; Katja Taxis; Sander D Borgsteede Journal: BMJ Open Date: 2016-10-12 Impact factor: 2.692
Authors: Justine M Z van Tongeren; S Froukje Harkes-Idzinga; Heleen van der Sijs; Roya Atiqi; Bart J F van den Bemt; L Willem Draijer; Deline Hiel; Adrian Kerremans; Bart Kremers; Marc de Leeuw; Marleen V Olthoff; T Kim-Loan Pham; Ricky Valentijn-Robertz; Kayan Tsoi; Iris Wichers; Maaike de Wit; Sander D Borgsteede Journal: Front Pharmacol Date: 2020-05-15 Impact factor: 5.810
Authors: Mette Heringa; Annemieke Floor-Schreudering; Hans Wouters; Peter A G M De Smet; Marcel L Bouvy Journal: Drug Saf Date: 2018-02 Impact factor: 5.606